Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents

JAMA

Volumn 297, Issue 18, 2007, Pages 2001-2009

  Win, Htut K ^a   Caldera, Angel E ^a   Maresh, Kelly ^b   Lopez, John ^c   Rihal, Charanjit S ^d   Parikh, Manish A ^c   Granada, Juan F ^b   Marulkar, Sachin ^e   Nassif, Deborah ^e   Cohen, David J ^f   Kleiman, Neal S ^b,g  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MAYO CLINIC   (United States)

^e HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^f SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^g MS F 1090   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PACLITAXEL; RAPAMYCIN; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; OFF LABEL DRUG USE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; ST SEGMENT ELEVATION; STENT THROMBOSIS; THROMBOSIS; TREATMENT OUTCOME;

EID: 34248376428     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.18.2001     Document Type: Article

References (27)

1. Director of Device Evaluation, Center for Devices and Radiologic Health to Mirjam van Werven, 24 April 2003. Rockville, Md. Cypher™ sirolimus-eluting coronary stents on RAPTOR® Rapid Exchange Deliver System. http://www.fda.gov/cdrh/PDF2/P020026A.PDF. Accessed January 10, 2007.
2. Director of Device Evaluation, Center for Devices and Radiologic Health to Douglas E. Ferguson, 4 March 2004. Rockville, Md. TAXUS™ Express2™ paclitaxel-eluting coronary stent system. http://www.fda.gov/ cdrh/pdf3/p030025a.pdf. Accessed January 10, 2007.
3. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-231.
4. Moses JW, Leon MB, Popma JJ, et al; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
5. Rao SV, Shaw RE, Brindis RG, et al. Patterns and outcomes of drug-eluting coronary stent use in clinical practice. Am Heart J. 2006;152:321-326.
6. Jacob S, Cohen DJ, Massaro J, Niemyski P, Maresh K, Kleiman N; EVENT Investigators. Design of a registry to characterize "real-world" outcomes of percutaneous coronary revascularization in the drug-eluting stent era. Am Heart J. 2005;150:887-892.
7. Bovill EG, Tracy RP, Knatterud GL, et al. Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina (Thrombolysis in Myocardial Ischemia, Phase IIIB Trial). Am J Cardiol. 1997;79:391-396.
8. Ellis SG, Vandormael MG, Cowley MJ; POSCH Group. Coronary morphologic and clinical determinates of procedural outcome with angioplasty for multivessel coronary disease: implications for patient selection. Circulation. 1990;82:1193-1202.
9. Rao SV, Shaw RE, Brindis RG, Klein LW, Weintraub WS, Peterson ED; American College of Cardiology National Cardiovascular Data Registry. On- versus off-label use of drug-eluting coronary stents in clinical practice (report from the American College of Cardiology National Cardiovascular Data Registry [NCDR]). Am J Cardiol. 2006;97:1478-1481.
10. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109:1244-1249.
11. Ge L, Iakovou I, Cosgrave J, et al. Immediate and mid-term outcomes of sirolimus-eluting stent implantation for chronic total occlusions. Eur Heart J. 2005;26:1056-1062.
12. Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol. 2006;47:871-877.
13. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: immediate and midterm outcome. J Am Coll Cardiol. 2005;45:989-994.
14. Fayers PM, Hand DJ. Generalisation from phase II clinical trials: survival, quality of life, and health economics. Lancet. 1997;350:1025-1027.
15. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-2809.
16. Nordman AJ, Briel M, Buc-her HC. Mortality in randomized controlled trials comparing drug-eluting vs bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J. 2006;27:2784-2814.
17. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med. 2007;356:1009-1019.
18. Cura FA, Bhatt DL, Lincoff AM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation. 2000;102:28-34.
19. Serruys PW, Lemos PA, van Hout BA. Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the Arterial Revascularisation Therapies Study part II (ARTS II). Heart. 2004;90:995-998.
20. Comparison of two treatments for multivessel coronary artery disease in individuals with diabetes (FREEDOM). http://www.clinicaltrials.gov/ct/show/ NCT00086450. Accessed January 10, 2007.
21. SYNTAX study: TAXUS drug-eluting stent versus coronary artery bypass surgery for the treatment of narrowed arteries. http://www.clinicaltrials.gov/ ct/show/NCT00114972?order=1. Accessed January 10, 2007.
22. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-1029.
23. Mahaffey KW, Roe MT, Dyke CK, et al; for the PARAGON B Investigators. Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Am Heart J. 2002;143:242-248.
24. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents. J Am Coll Cardiol. 2006;48:2584-2591.
25. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-168.
26. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-678.
27. Filmore D. Hospital survey illustrates drug-eluting stent use decline in fourth quarter. The Gray Sheet. 2007;33:11.